AbbVie’s Maviret ends the wait-and-see reality for acute HCV

RegulatoryapprovedMaviret/MavyretPositive

AI Analysis

Summary

AbbVie's Mavyret (glecaprevir/pibrentasvir) received EU approval for an expanded indication to treat both acute and chronic hepatitis C, eliminating the need to wait for chronicity confirmation before treatment initiation and aligning with clinical recommendations.

Outcome Details

EU approval for expanded indication to include acute HCV, in addition to chronic HCV

Importance:6/10

Sentiment:

0.70

regulatory approvalindication expansionHCVEUMaviretAbbVie

Related Companies

$ABBV

Read the original article

Published by Drug Discovery & Development on July 30, 2026 5:53 PM

Read Original